BioSpace News Archive

Lipella Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10.

CRISPR Therapeutics today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET.

Tevogen Bio Holdings Inc announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development.

BioVaxys Technology Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a Patent (“Patent”) for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulate with DPX™.

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.

InspireMD, Inc. today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.

Clearday (OTCQX CLRD) A technology-enabled healthcare services company is pleased to announce that it has been invited to present at the Emerging Growth Conference on Thursday, April 4, 2024.

Merus N.V. today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039.